文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

口服雷尼替丁对尿中N-亚硝基二甲胺排泄的影响:随机临床试验

Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机双盲安慰剂对照交叉试验纳入18名健康参与者,比较口服雷尼替丁300 mg与安慰剂后24小时尿中NDMA排泄量。结果显示,在非腌制肉类饮食和腌制肉类饮食条件下,雷尼替丁与安慰剂组间NDMA排泄均无统计学显著差异,未报告药物相关严重不良事件。

要点

  • 健康人服用雷尼替丁300 mg后24小时尿NDMA排泄与安慰剂无显著差异。

核心结论

  • 口服雷尼替丁300 mg与安慰剂相比,未显著增加健康参与者24小时尿NDMA排泄量。
  • 研究结果不支持雷尼替丁在一般健康人群中转化为NDMA。

研究设计与样本

  • 随机、双盲、安慰剂对照、交叉临床试验,在临床药理学单元(美国威斯康星州West Bend)进行。
  • 纳入18名健康参与者,随机分配至4种治疗顺序之一,在4个周期内分别接受雷尼替丁300 mg和安慰剂,并配合非腌制肉类饮食或腌制肉类饮食。
  • 主要结局为24小时尿NDMA排泄量;17名(94%)参与者完成试验。

主要发现

  • 未报告药物相关严重不良事件。

临床怎么用

  • 该试验结果不支持口服雷尼替丁在健康人群中转化为NDMA,可为评估雷尼替丁安全性提供参考。
  • 临床决策应结合其他药理学和流行病学证据综合判断。

局限性

  • 样本量较小,仅纳入18名健康参与者。
  • 研究仅在健康人群中进行,未涉及患者群体。
  • 饮食干预(非腌制肉类与腌制肉类)可能影响NDMA暴露水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In 2019, the US Food and Drug Administration (FDA) received a citizen petition indicating that ranitidine contained the probable human carcinogen N-nitrosodimethylamine (NDMA). In addition, the petitioner proposed that ranitidine could convert to NDMA in humans; however, this was primarily based on a small clinical study that detected an increase in urinary excretion of NDMA after oral ranitidine consumption. OBJECTIVE: To evaluate the 24-hour urinary excretion of NDMA after oral administration of ranitidine compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, crossover clinical trial at a clinical pharmacology unit (West Bend, Wisconsin) conducted in 18 healthy participants. The study began in June 2020, and the end of participant follow-up was July 1, 2020. INTERVENTIONS: Participants were randomized to 1 of 4 treatment sequences and over 4 periods received ranitidine (300 mg) and placebo (randomized order) with a noncured-meats diet and then a cured-meats diet. The cured-meats diet was designed to have higher nitrites, nitrates (nitrate-reducing bacteria can convert nitrates to nitrites), and NDMA. MAIN OUTCOME AND MEASURE: Twenty-four-hour urinary excretion of NDMA. RESULTS: Among 18 randomized participants (median age, 33.0 [interquartile range {IQR}, 28.3 to 42.8] years; 9 women [50%]; 7 White [39%], 11 African American [61%]; and 3 Hispanic or Latino ethnicity [17%]), 17 (94%) completed the trial. The median 24-hour NDMA urinary excretion values for ranitidine and placebo were 0.6 ng (IQR, 0 to 29.7) and 10.5 ng (IQR, 0 to 17.8), respectively, with a noncured-meats diet and 11.9 ng (IQR, 5.6 to 48.6) and 23.4 ng (IQR, 8.6 to 36.7), respectively, with a cured-meats diet. There was no statistically significant difference between ranitidine and placebo in 24-hour urinary excretion of NDMA with a noncured-meats diet (median of the paired differences, 0 [IQR, -6.9 to 0] ng; P = .54) or a cured-meats diet (median of the paired differences, -1.1 [IQR, -9.1 to 11.5] ng; P = .71). No drug-related serious adverse events were reported. CONCLUSIONS AND RELEVANCE: In this trial that included 18 healthy participants, oral ranitidine (300 mg), compared with placebo, did not significantly increase 24-hour urinary excretion of NDMA when participants consumed noncured-meats or cured-meats diets. The findings do not support that ranitidine is converted to NDMA in a general, healthy population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397445.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Florian J, Matta MK, DePalma R, et al. Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial. JAMA. 2021. PMID: 34180947. doi:10.1001/jama.2021.9199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。